Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2007 Jul 15;17(14):3997-4000. Epub 2007 Apr 29.

Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.

Author information

1
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. kevin_nguyen@merck.com

Abstract

A novel series of cyclic benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity. Compound 29 is orally active in a carrageenan-induced rat hyperalgesia model of pain.

PMID:
17498948
DOI:
10.1016/j.bmcl.2007.04.084
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center